CompletedNot Applicable

Radiation-induced Diarrhoea During Curative EBRT of Prostate and Rectal Cancer

Denmark40 participantsStarted 2022-06-01

Plain-language summary

Approx. 80% of patients with prostate and rectal cancer who receive radiation therapy (RT) experience acute radiation-induced diarrhea (RID). RID has major impact on patients' quality of life, can lead to pause or early termination of RT and chronic diarrhea. RID is poorly described with few details of type and severity of RID in clinical practice and in the literature. We are conducting an observational study in patients in patients who receive curative EBRT radiation for prostate and rectal cancer to uncover the frequency and classifications of RID.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Histopathologically verified prostate or rectal adenocarcinoma
✓. Commenced to start curative EBRT to the pelvis, with or without chemotherapy or with or without androgen deprivation therapy (ADT)
✓. Performance status 0-1
✓. ≥ 18 years of age
✓. Understanding and acceptance of written and orally informed consent in Danish

Exclusion criteria

✕. Earlier treated with EBRT or other type of radiation to the pelvis
✕. History of diagnosed inflammatory bowel disease
✕. Colostomy
✕. Pregnancy

What they're measuring

Frequency and classification of radiation-induced diarrhrea in patients with prostate and rectal cancer during curative external radiotherapy

Timeframe: 1 June 2022 - 31 December 2023

Trial details

NCT IDNCT05684432

SponsorAalborg University Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-07-31

View on ClinicalTrials.gov More Radiation-induced Diarrhoea in Prostate and Rectal Cancer trials